News stories about Genetic Technologies (NASDAQ:GENE) have trended somewhat positive on Saturday, according to Accern Sentiment Analysis. Accern identifies negative and positive press coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Genetic Technologies earned a daily sentiment score of 0.13 on Accern’s scale. Accern also assigned media coverage about the biotechnology company an impact score of 45.9569969579776 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
Shares of Genetic Technologies (NASDAQ GENE) traded down $0.04 during trading on Friday, hitting $1.74. 450,519 shares of the stock were exchanged, compared to its average volume of 919,856. Genetic Technologies has a 12 month low of $0.70 and a 12 month high of $2.05.
ILLEGAL ACTIVITY WARNING: “Genetic Technologies (GENE) Getting Somewhat Favorable News Coverage, Analysis Shows” was originally reported by Ticker Report and is the sole property of of Ticker Report. If you are viewing this piece on another site, it was copied illegally and reposted in violation of US & international trademark and copyright legislation. The legal version of this piece can be read at https://www.tickerreport.com/banking-finance/3147697/genetic-technologies-gene-getting-somewhat-favorable-news-coverage-analysis-shows.html.
Genetic Technologies Company Profile
Genetic Technologies Limited is a molecular diagnostics company. The Company is engaged in the provision of molecular risk assessment for cancer. The Company offers predictive testing and assessment tools for physicians to manage women’s health. The Company’s lead product, BREVAGenplus, is a clinically validated risk assessment test for non-hereditary breast cancer.
Receive News & Ratings for Genetic Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genetic Technologies and related companies with MarketBeat.com's FREE daily email newsletter.